<DOC>
	<DOCNO>NCT00267722</DOCNO>
	<brief_summary>The purpose study evaluate intravenous ( injection ) investigational medication treat moderate severe inflammatory , nonstricturing , nonpenetrating Crohn 's disease . The research conduct 5 clinical research sit US Europe open men woman age 18 70 year old . Participants study number visit research site 17 month . All study-related care medication provide qualified participant cost : include visit , examination laboratory work . Visilizumab humanize antibody ( antibody proteins normally make immune system help defend body infection foreign substance ) direct T cell . Visilizumab selectively attack problematic T cell , , may prevent cause inflammation . Visilizumab also observe suppressive effect body 's immune system ( system body react foreign occasionally one 's protein ) .</brief_summary>
	<brief_title>Visilizumab Moderate Severe Inflammatory , Nonstricturing , Nonpenetrating Crohn 's Disease</brief_title>
	<detailed_description>PDL BioPharma , Inc. formerly know Protein Design Labs , Inc .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>1870 year old Diagnosis moderatetosevere inflammatory , nonstricturing , nonpenetrating Crohn 's disease , define Crohn 's Disease Activity Index great equal 250 , Creactive protein great equal upper limit normal , endoscopic evidence moderatetosevere active inflammatory disease Test negative Clostridium difficile within 3 week Signed informed consent , include permission use protect health information History lymphoproliferative disorder prior malignancy within 5 year current malignancy Pregnant nursing HIV , Hepatitis B Hepatitis C infection Presence obstructive symptom , confirm endoscopy Serious infection within 12 month Active infection require antibiotic therapy Started change dose sulfasalazine , 5aminosalicylic acid ; antibiotic , probiotic , topical therapy Crohn 's within 2 week Serious infection require IV antibiotic therapy hospitalization within 8 week Increase dose corticosteroid medication within 2 week Received live vaccine within 6 week Received monoclonal antibody investigational agent within 3 month Received cyclosporine tacrolimus ( FK506 ) within 4 week Dose change discontinuation 6mercaptopurine , azathioprine , methotrexate within 4 week Significant organ dysfunction Likely require surgery next 6 month History lymphoproliferative disorder History tuberculosis mycobacteria infection positive chest xray History thrombophlebitis pulmonary embolus History immune deficiency autoimmune disorder Crohn 's History subtherapeutic blood level anticonvulsive medication within 1 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>